{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:05Z","timestamp":1767485765252,"version":"3.48.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06708-0","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:17:46Z","timestamp":1765592266000},"page":"6463-6466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting relapsed\/refractory and MRD\u2009+\u2009Ph\u2009+\u2009ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome\u200b"],"prefix":"10.1007","volume":"104","author":[{"given":"Xiaoyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"6708_CR1","doi-asserted-by":"publisher","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1306494","DOI":"10.1056\/NEJMoa1306494"},{"issue":"11","key":"6708_CR2","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","volume":"25","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Advani AS, Bachanova V et al (2019) Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant 25(11):2113\u20132123. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"6708_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H et al (2017) Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol (7):e170580. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"6708_CR4","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1182\/blood-2022-166482","volume":"140","author":"W Liu","year":"2022","unstructured":"Liu W, Liu Y, Zhu Y et al (2022) The first report of third-generation TKI olverembatinib in adult Ph\/BCR-ABL1-positive acute lymphoblastic leukemia with T315I mutation and relapsed disease. Blood 140(Supplement 1):3266\u20133267. https:\/\/doi.org\/10.1182\/blood-2022-166482","journal-title":"Blood"},{"issue":"6","key":"6708_CR5","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.cd-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E et al (2021) Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1465","journal-title":"Cancer Discov"},{"key":"6708_CR6","doi-asserted-by":"publisher","unstructured":"Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B (2022) The emerging role of Venetoclax-Based treatments in acute lymphoblastic leukemia. International J Mol Sciences Sep 19(18). https:\/\/doi.org\/10.3390\/ijms231810957","DOI":"10.3390\/ijms231810957"},{"issue":"7","key":"6708_CR7","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1002\/ajh.26175","volume":"1","author":"NJ Short","year":"2021","unstructured":"Short NJ, Konopleva M, Kadia T et al (2021) An effective chemotherapy-free regimen of Ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. American J Hematology Jul 1(7):E229\u2013E232. https:\/\/doi.org\/10.1002\/ajh.26175","journal-title":"American J Hematology Jul"},{"issue":"1","key":"6708_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00621-9","volume":"28","author":"H Wang","year":"2022","unstructured":"Wang H, Yang C, Shi T et al (2022) Venetoclax-ponatinib for T315I\/compound-mutated Ph\u2009+\u2009acute lymphoblastic leukemia. Blood Cancer J 28(1):20. https:\/\/doi.org\/10.1038\/s41408-022-00621-9","journal-title":"Blood Cancer J"},{"issue":"9","key":"6708_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","volume":"1","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H (2022) Treatment of adults with Philadelphia Chromosome-Positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol 1(9):1340\u20131348. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2398","journal-title":"JAMA Oncol"},{"issue":"1","key":"6708_CR10","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/s2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N et al (2023) Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24\u2013e34. https:\/\/doi.org\/10.1016\/s2352-3026(22)00319-2","journal-title":"Lancet Haematol"},{"issue":"6","key":"6708_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/ajh.27289","volume":"99","author":"H Tang","year":"2024","unstructured":"Tang H, Jia W, Jia S et al (2024) A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph\u2009+\u2009acute lymphoblastic leukemia: preliminary outcomes of a prospective study. Am J Hematol 99(6):1177\u20131179. https:\/\/doi.org\/10.1002\/ajh.27289","journal-title":"Am J Hematol"},{"issue":"1","key":"6708_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01211-1","volume":"8","author":"N Parry","year":"2022","unstructured":"Parry N, Busch C, A\u00dfmann V et al (2022) BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discov (1):457. https:\/\/doi.org\/10.1038\/s41420-022-01211-1","journal-title":"Cell Death Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06708-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06708-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06708-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:11Z","timestamp":1767485711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06708-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6708"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06708-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}